Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests begin for potential neurological disorder drug

NCT ID NCT05938452

Summary

This early-stage study aims to test the safety of a new capsule called GTB in healthy people. Researchers will give 40 volunteers single and multiple doses to see how their bodies react and process the drug. The main goal is to check for side effects and determine safe dosage levels before testing in patients with neurological conditions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROLOGICAL DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • TKL Research

    Bloomfield, New Jersey, 07003, United States

Conditions

Explore the condition pages connected to this study.